#AACR17: Basket Trial for Experimental Drug Shows Promising Early Results
First, at this week's #AACR17 press conference: David Hyman, MD, from @sloan_kettering presented data from a phase II basket trial.
I'm going to quote heavily here from the article's intro to the story of SUMMIT phase 2 study.:
"Neratinib, an experimental drug developed to target certain mutations that drive cancer growth, is showing promise for treating several types of cancer. The findings from a phase II study were presented at the 2017 AACR Annual Meeting."
" Basket trials are based on the idea that cancers originating in different parts of the body may carry the same genetic mutations.
Neratinib, the drug in this study, targets mutations in a protein called HER2.
Researchers think the drug will work even better if it’s combined with other therapies".
(Not the same HER2 we've been thinking of in breast cancer.)
Breast Cancer, cervical cancer, and biliary cancer showed the best results - some tumors shrunk, some stopped growing. Which leads us to a story from Dr. Robin Gillespie, a scientist who has taken the drug for two years!
After chemo and having a lung removed, she had no other conventional choices. She was tested for mutations that might qualify her for a clinical trial, she came to SK.
Metastatic since 2011:
https://www.mskcc.org/blog/aacr17-novel-trial-experimental-drug-shows-promising-early-results?utm_source=Twitter&utm_medium=Organic&utm_campaign=040217PhotoAACRHyman&utm_content=Research&sf67394656=1
I'm going to quote heavily here from the article's intro to the story of SUMMIT phase 2 study.:
"Neratinib, an experimental drug developed to target certain mutations that drive cancer growth, is showing promise for treating several types of cancer. The findings from a phase II study were presented at the 2017 AACR Annual Meeting."
" Basket trials are based on the idea that cancers originating in different parts of the body may carry the same genetic mutations.
Breast Cancer, cervical cancer, and biliary cancer showed the best results - some tumors shrunk, some stopped growing. Which leads us to a story from Dr. Robin Gillespie, a scientist who has taken the drug for two years!
After chemo and having a lung removed, she had no other conventional choices. She was tested for mutations that might qualify her for a clinical trial, she came to SK.
Metastatic since 2011:
Her tumors have stopped growingShe has almost no side effectsShe can take the medicine as pills You might enjoy her study - and have a look at the whole article.
I wish you health.
I wish you health.
https://www.mskcc.org/blog/aacr17-novel-trial-experimental-drug-shows-promising-early-results?utm_source=Twitter&utm_medium=Organic&utm_campaign=040217PhotoAACRHyman&utm_content=Research&sf67394656=1
No comments:
Post a Comment